Compare BioNTech SE - ADR (BNTX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs United Microelectronics Corp — how do they compare? BioNTech SE - ADR trades at $93.32 (market cap $23.31B), while United Microelectronics Corp trades at $19.51 (market cap $47.81B). The key difference: United Microelectronics Corp is far larger — about 2.1× BioNTech SE - ADR's market cap, and United Microelectronics Corp pays a 2.12% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | UMC | |
|---|---|---|
Market Cap | $23.31B | $47.81B |
Sector | Health | Technology |
52-Week High | $119.34 | $28.02 |
52-Week Low | $83.89 | $6.58 |
Enterprise Value | $6.60B | $44.93B |
Dividend Yield | — | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
UMC trades at $19.40, up 3.25% with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.54 EPS, and announced fab expansions in Singapore and Taiwan to meet AI demand. Revenue growth is projected to rise to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow turned positive in 2025 at $5.66 billion, supporting strategic investments.
Outlook is positive due to AI-driven demand and operational execution, but risks include competitive pressures and capital expenditure volatility. Analysts show mixed sentiment with 26.7% buy ratings, highlighting cautious optimism amid expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
